Coenzyme Q10 as Treatment for Long Term COVID-19

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, placebo-controlled, double-blinded, cross-over designed clinical trial investigating the effect of high-dose Coenzyme Q10 treatment in subjects with persisting symptoms more than 12 weeks af SARS-CoV-2 infection, Long Term COVID-19 (LTC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aarhus University Hospital
• Collaborators: Pharma Nord; University of Aarhus
• Treatments: Coenzyme Q10; Ubiquinone

Criteria

Inclusion Criteria:

• Age above 18 years.

• Able to give informed consent.

• History of documented SARS-CoV-2 infection either by RT-PCR or antibody test.

• Symptoms related to Long Term COVID-19, defined as being investigated, diagnosed and followed by specialized infectious diseases physicians in the Long Term COVID-19 Outpatient Clinic, Central Region of Denmark, Aarhus University Hospital.

• Symptoms not attributable to other co-morbidity/condition.

Exclusion Criteria:

• Symptoms of acute COVID-19, as defined by The Danish Health Authorities.

• Women who are pregnant or breastfeeding, or with a positive pregnancy test as determined by a positive urine beta-human chorionic gonadotropin test during screening

• Hypersensitivity to the active ingredient or to any excipient of the medicinal product

• Known allergy to soy or peanuts.

• Individuals with reduced kidney or liver-function.

• Patients in anticoagulant therapy with vitamin K antagonists.

• Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy.